Hepatitis C Virus Clinical Trials

184 clinical trials for Hepatitis C Virus across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data — RECRUITING
• California MEPS Hub — RECRUITING · NA
• Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons — RECRUITING · NA
• PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF BEMNIFOSBUVIR-RUZASVIR FIXED-DOSE COMBINATION (BEM/RZR FDC) VERSUS SOFOSBUVIR-VELPATASVIR FIXED-DOSE COMBINATION (SOF/VEL FDC) IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION — RECRUITING · PHASE3
• Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening — RECRUITING · NA
• SAFETY, TOLERABILITY, AND OUTCOMES OF VELPATASVIR/SOFOSBUVIR IN TREATMENT OF CHRONIC HEPATITIS C VIRUS DURING PREGNANCY (STORC):A SINGLE-ARM, SINGLE-CENTER, OPEN LABEL PHASE 1 STUDY OF A 12-WEEK COURSE OF SOF/VEL IN 10 HCV-INFECTED PREGNANT WOMEN. — RECRUITING · PHASE1
• A PHASE II, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMENT OF MK-3682B (MK-5172 + MK-3682 + MK-8408 FIXED DOSE COMBINATION (FDC)) IN SUBJECTS WITH CHRONIC HCV GT1 OR GT3 INFECTION WHO HAVE FAILED A DIRECT ACTING ANTIVIRAL REGIMEN — RECRUITING · PHASE2
• A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN RENALLY-IMPAIRED ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 ¿ 6 INFECTION (EXPEDITION-5) — RECRUITING
• A PHASE 2, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF 12 WEEKS OF THE COMBINATION REGIMEN OF MK-3682 + MK-8408 IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION — RECRUITING · PHASE2
• A PHASE IA/IB STUDY ASSESSING SINGLE AND MULTIPLE DOSES OF CDI-31244, A NON-NUCLEOSIDE INHIBITOR IN HEALTHY AND HEPATITIS C VIRUS-INFECTED SUBJECTS — RECRUITING · PHASE1
• SIMPLIFY: A PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTRE, INTERNATIONAL TRIAL OF SOFOSBUVIR AND GS-5816 FOR PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTION DRUG USE — RECRUITING · PHASE2
• A PHASE III RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172/MK-8742 IN SUBJECTS WHO HAVE FAILED PRIOR TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN (P/R) WITH CHRONIC HCV GT1, GT4, GT5, AND GT6 INFECTION — RECRUITING · PHASE3
• A PHASE III OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172/MK-8742 IN TREATMENT-NAÏVE SUBJECTS WITH CHRONIC HCV GT1, GT4, GT5, AND GT6 INFECTION WHO ARE CO-INFECTED WITH HIV — RECRUITING · PHASE3
• A PHASE II/III RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND CHRONIC KIDNEY DISEASE — RECRUITING
• A PHASE II RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 +/-RIBAVIRIN (RBV) IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS INFECTION — RECRUITING · PHASE2
• TMC435HPC3002 - 3-Year Follow up of Patients After Administration of TMC435 for the Treatment of Chronic Hepatitis C. — COMPLETED · PHASE3
• A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection — COMPLETED · PHASE2
• A first-in-human trial of IDX21437, a new study drug being evaluated for hepatitis C virus infection. — COMPLETED · PHASE2
• Genotype and Subtype Mapping of the Hepatitis C Virus — NOT_YET_RECRUITING
• Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment — ACTIVE_NOT_RECRUITING
• Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System — NOT_YET_RECRUITING
• Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans — NOT_YET_RECRUITING · NA
• MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo — NOT_YET_RECRUITING
• A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus — COMPLETED
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) — COMPLETED · PHASE3
• Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil — COMPLETED
• Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment — ACTIVE_NOT_RECRUITING · PHASE4
• A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers — COMPLETED
• Acceptance and Feasibility of Hepatitis c Screening Strategies in Social Insertion Centers — OTHER · NA
• Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population — COMPLETED
• Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis — OTHER
• Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response — COMPLETED
• A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF BEMNIFOSBUVIR (BEM) AND RUZASVIR (RZR) IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION — COMPLETED · PHASE2
• A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection — COMPLETED · PHASE2
• A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation — COMPLETED
• Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis — COMPLETED
• RANDOMISED, OPEN-LABEL AND PARALLEL GROUP TRIAL TO INVESTIGATE THE EFFECTS OF ORAL BI 685509 ALONE OR IN COMBINATION WITH EMPAGLIFLOZIN ON PORTAL HYPERTENSION AFTER 8 WEEKS TREATMENT IN PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION (CSPH) IN COMPENSATED CIRRHOSIS — NOT_YET_RECRUITING
• Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea — COMPLETED
• The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects — COMPLETED
• Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea — COMPLETED
• Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6 — COMPLETED
• Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection — COMPLETED · PHASE4
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection — COMPLETED · PHASE2
• A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection — COMPLETED · PHASE3
• Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection — COMPLETED · PHASE3
• A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection — COMPLETED · PHASE3
• A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection — COMPLETED · PHASE3
• A MULTICENTER, SINGLE-ARM PROSPECTIVE STUDY TO EVALUATE SAFETY AND EFFICACY OF GLE/PIB 8-WEEK TREATMENT IN ADULTS AND ADOLESCENTS WITH ACUTE HEPATITIS C VIRUS (HCV) INFECTION — COMPLETED

Refine this search